SOURCE: WallStreetActive.Com

November 28, 2012 08:00 ET

Analyst Opinion on Mylan and Medicis Pharmaceutical - Acquisitions and Approvals Abound in Generic Drug Industry

LONDON--(Marketwire - Nov 28, 2012) - The drugs - generic industry, within which Mylan Inc. (NASDAQ: MYL) and Medicis Pharmaceutical Corporation (NYSE: MRX) evolve, has been bustling with activity recently. Several companies have had their generic equivalents approved by the FDA while others have been involved in mergers and acquisitions. is unswerving when it comes to teaching the new and pro traders on how to take the helm in a market environment that has been seeing waves upon waves of changes and reap the rewards of participating in various sectors. We invite serious traders to join our financial community so that they can benefit from our free analytical coverage on Mylan and Medicis Pharmaceutical by signing up at 

On the approval side of things, Mylan has been busy. The company recently stated that, through one of its subsidiaries, it has received final approval from the FDA for its generic version of Pfizer's Revatio®. The company also has 172 Abbreviated New Drug Applications awaiting FDA approval, including a number of potential first-to-file applications. Analyst opinion on Mylan Inc. accessible for free at

Merger and acquisition activities have been robust in the industry, as acquisitions cut out lengthy and expensive research and development and instantly bolster product portfolios. Medicis is one step closer to being acquired by Valeant Pharmaceuticals International, as the U.S. Federal Trade Commission recently completed its review of the potential acquisition and granted early termination of the waiting period without conditions. The acquisition still needs to be approved by Medicis' stockholders. See what our analysts have to say on Medicis Pharmaceutical Corporation. Follow the Link below

About Wall Street Active:
Wall Street Active offers topmost independent research and investment strategies with the sole purpose of consistently identifying stocks that provide the biggest return on investment for our subscribers. We provide sharp North American stock investing opinion with a truly outstanding success rate. Our goal is for likeminded traders to make a lot of money through our information.

Read our Disclaimer

Contact Information